Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LENSAR, INC.

(LNSR)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 02-02-2023
3.160 USD   +3.61%
2022Transcript : LENSAR, Inc., Q3 2022 Earnings Call, Nov 09, 2022
CI
2022LENSAR, Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
2022Lensar, Inc. Kondigt certificering aan van het Ally Adaptive Cataract Treatment System in de Eu
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op LENSAR, INC.
13/01Lensar, Inc. : Change in Directors or Principal Officers (form 8-K)
2022LENSAR to Present at Two Upcoming Investor Conferences
2022Lensar : November 2022 Corporate Presentation
2022LENSAR, INC. Management's Discussion and Analysis of Financial Condition and Results o..
2022LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2022Earnings Flash (LNSR) LENSAR Posts Q3 Revenue $7.7M, vs. Street Est of $7.9M
2022LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
2022LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022
2022LENSAR, Inc.(NasdaqCM:LNSR) dropped from S&P Global BMI Index
2022LENSAR Applies for EU Certification of ALLY Adaptive Cataract Treatment System
2022Lensar, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (..
2022Lensar, Inc. Announces Application for Certification of the Ally Adaptive Cataract Trea..
2022LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Tre..
2022Lensar : First Patients Treated with LENSAR'sģ ALLY™ Adaptive Cataract Treatment Sys..
2022Lensar, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (..
2022First Patients Treated with LENSAR'sģ ALLY™ Adaptive Cataract Treatment System
2022LENSAR, Inc. Announces First Patients Treated with LENSAR's(R) ALLY(TM) Adaptive Catara..
2022LENSAR, INC. Management's Discussion and Analysis of Financial Condition and Results o..
2022Lensar : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form..
2022LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June ..
2022Earnings Flash (LNSR) LENSAR Reports Q2 Revenue $8M
2022LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update
2022LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
2022Lensar, Inc. : Other Events (form 8-K)
2022LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 3000E Value Index
2022LENSAR, Inc.(NasdaqCM:LNSR) added to Russell 3000E Growth Index
2022LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell Microcap Value In..
2022LENSAR, Inc.(NasdaqCM:LNSR) added to Russell Microcap Growth Index
2022Lensar : reg; Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment Syste..
2022Lensar, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (..
2022LENSAR Secures FDA Clearance of ALLY Adaptive Cataract Treatment System
2022LENSARģ Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System
2022LENSAR, Inc. Receives U.S. FDA Clearance of Ally(Tm) Adaptive Cataract Treatment System
2022Lensar Gets FDA 510(k) Clearance for ALLY Adaptive Cataract Treatment System
2022Lensar, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
2022LENSAR, INC. Management's Discussion and Analysis of Financial Condition and Results ..
2022LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Earnings Flash (LNSR) LENSAR Posts Q1 Revenue $9.3M, vs. Street Est of $8.71M
2022LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update
2022LENSAR to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
2022LENSAR, INC. Management's Discussion and Analysis of Financial Condition and Results o..
2022Lensar : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business..
2022LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
2022LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
2022Earnings Flash (LNSR) LENSAR Reports Q4 Revenue $11.2M, vs. Street Est of $8.9M
2022LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Busines..
2022Lensar, Inc. : Other Events (form 8-K)
2022LENSAR Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ..
2022LENSAR, Inc. Announces U.S. Food and Drug Administration Acceptance of 510(k) Submissio..
2022LENSAR to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March..
2022LENSAR to Participate in Two Upcoming Investor Conferences
2022Lensar Names Kendra Wong Principal Accounting Officer
2022Lensar, Inc. : Change in Directors or Principal Officers (form 8-K)
2022LENSAR, Inc. Appoints Kendra W. Wong as Principal Accounting Officer
2022LENSAR to Present at the H.C. Wainwright Virtual BioConnect Conference
2021LENSAR to Present at Two Upcoming Investor Conferences
2021LENSAR Announces Poster Presentations at the American Academy of Ophthalmology
2021LENSAR, Inc Corporate Presentation
2021LENSAR, INC. Management's Discussion and Analysis of Financial Condition and Results ..
2021LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update - Form..
2021LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update
2021Earnings Flash (LNSR) LENSAR Reports Q3 Revenue $8.3M, vs. Street Est of $7.67M
2021LENSAR to Report Third Quarter 2021 Financial Results on Monday, November 8, 2021
2021Lensar : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021Lensar : to Present at the H.C. Wainwright Ophthalmology Virtual Conference
2021Lensar : Corporate Presentation
2021Lensar : Management's Discussion and Analysis of Financial Condition and Results of Operat..
2021Lensar, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
2021LENSAR : Earnings Flash (LNSR) LENSAR Posts Q2 Revenue $7.9M, vs. Street Est of $..
2021Lensar : Reports Second Quarter 2021 Financial Results and Provides Business Update
2021Lensar : to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021Lensar : Announces In-Person Demonstrations of Its Next Generation ALLY™ System and ..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell Small Cap Complet..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell Small Cap Comp Va..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 3000 Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 3000 Value Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 3000E Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Dynamic Inde..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Value-Defens..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Defensive In..
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2500 Value Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Value Index
2021LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2500 Index
2021Lensar : to Present at the Oppenheimer MedTech, Tools, & Diagnostics Summit
2021Lensar, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
2021Lensar : Management's Discussion and Analysis of Financial Condition and Results of Operat..
2021LENSAR : Earnings Flash (LNSR) LENSAR Posts Q1 Revenue $7M, vs. Street Est of $6...
2021Lensar : Reports First Quarter 2021 Financial Results and Provides Business Update
2021LENSAR, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2021
2021Lensar : to Hold First Quarter 2021 Financial Results Conference Call on Wednesday, May 5,..
2021Lensar, Inc. : Change in Directors or Principal Officers (form 8-K)
2021Lensar : Annual Report (SEC Filing - 10-K)
2021Lensar : Management's Discussion and Analysis of Financial Condition and Results of Operat..
2021LENSAR : Earnings Flash (LNSR) LENSAR Reports Q4 Revenue $8.3M, vs. Street Est of..
2021Lensar : Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business..
2021LENSAR, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended Dece..
2021Lensar : to Hold Fourth Quarter and Full Year 2020 Financial Results and Business Update C..
2021Lensar : to Present at Two Upcoming Investor Conferences
2021Lensar, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financ..
Volgende evenement op LENSAR, INC.